Featured Research

from universities, journals, and other organizations

Chemical Cousin Of Anti-anxiety Drugs Holds Promise For Psoriasis Treatment

Date:
January 3, 2005
Source:
University Of Michigan
Summary:
A new drug candidate previously shown to reduce harmful side effects of the autoimmune disease lupus also may be useful in treating psoriasis.

ANN ARBOR, Mich. -- A new drug candidate previously shown to reduce harmful side effects of the autoimmune disease lupus also may be useful in treating psoriasis.

In a study published online Dec. 2 in the issue in the of the Journal of Pharmacology and Experimental Therapeutics, scientists from the University of Michigan report that a compound called benzodiazepine-423 (Bz-423)—a chemical cousin of the anti-anxiety drugs Valium™ and Xanax™—suppresses cell growth in a model of psoriasis. In that disease psoriasis, cells multiply unchecked , so inhibiting cell growth should help control the disease.

Psoriasis is a life-long genetic condition that affects the skin and joints. More than 4.5 million people in the United States have psoriasis or an associated form of arthritis, and the economic burden of the disease may be as high as $4.3 billion a year, according to the National Psoriasis Foundation.

"Currently, the best treatments for skin lesions associated with psoriasis are topical steroids, but the problem with those drugs is that they're not selective for the disease-causing cells. They affect normal cells as well, and repeated use over time can lead to tissue destruction," said Gary Glick, who is the Werner E. Bachmann Collegiate Professor of Chemistry and a professor of biological chemistry in the U-M Medical School. "There are also protein drugs approved for use in treating psoriasis, but those drugs are injected instead of applied topically, which makes them more costly, less convenient and more likely to cause side effects since they are delivered throughout the body. "

"What makes our compound particularly exciting is that it has the potential to be applied topically, and it shows very good selectivity for models of the disease-causing cells versus normal cells," said Glick said. "So we believe the problems associated with repeated topical steroid use could possibly be alleviated with compounds like this. "

Bz-423 has not yet been tested in people; the experiments described in the journal article were done on organ cultures of human skin designed to model psoriasis. However, said Glick, "with the data we have now and other data that we're in the process of collecting, we hope to start a clinical trial in the near future."

The compound might also be added to Retin-A (retinoic acid), which is used to treat acne and skin damage due to sun exposure. "One of the problems with retinoic acid is that, while it 's very effective, it can also cause effects similar to psoriasis, so people often stop using it," said Glick said. "Because the biological basis of retinoic acid hyperplasia (a reddening of the skin similar to inflammation) is very similar to that of psoriasis, the potential exists for our compound to be mixed with Retin-A to prevent these unwanted effects. "

In 2003, Florida-based GMP Immunotherapeutics, Inc. (a subsidiary of GMP Companies, Inc.) entered into an exclusive patent license and a sponsored research agreement with the University of Michigan to develop Bz-423 and other compounds for treatment of lupus, rheumatoid arthritis, psoriasis and some forms of cancer. Glick and collaborators at U-M also are using the compounds to explore fundamental biological questions about the origins of such diseases.

Glick's coauthors on the paper are James Varani, professor of pathology; Narasimharao Bhagavathula, a research investigator in the pathology department; Hilary Scherzer and Kevin Fay, research associates in pathology; Kent Johnson, professor of pathology; Sewon Kang, professor of dermatology; and Anthony Opipari, assistant professor of obstetrics and gynecology. Glick and Opipari are shareholders in GMP.

The research was funded in part by the U.S. Public Health Service.


Story Source:

The above story is based on materials provided by University Of Michigan. Note: Materials may be edited for content and length.


Cite This Page:

University Of Michigan. "Chemical Cousin Of Anti-anxiety Drugs Holds Promise For Psoriasis Treatment." ScienceDaily. ScienceDaily, 3 January 2005. <www.sciencedaily.com/releases/2004/12/041220003823.htm>.
University Of Michigan. (2005, January 3). Chemical Cousin Of Anti-anxiety Drugs Holds Promise For Psoriasis Treatment. ScienceDaily. Retrieved April 24, 2014 from www.sciencedaily.com/releases/2004/12/041220003823.htm
University Of Michigan. "Chemical Cousin Of Anti-anxiety Drugs Holds Promise For Psoriasis Treatment." ScienceDaily. www.sciencedaily.com/releases/2004/12/041220003823.htm (accessed April 24, 2014).

Share This



More Health & Medicine News

Thursday, April 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins